论文部分内容阅读
目的探讨酪氨酸激酶受体在卵巢癌中的表达及意义。方法应用免疫组化SP方法,检测20例正常卵巢组织和60例卵巢癌中酪氨酸激酶受体C-kit、C-abl和PDGFRα的表达。结果至少含一种酪氨酸激酶受体的阳性率为79%;C-kit、C-abl和PDGFRα在卵巢癌中阳性表达率分别为58.3%,70%,73.3%,其中C-kit和PDGFRα蛋白的阳性表达率较高,明显高于正常卵巢组织,差异有显著性(P<0.01)。C-abl在卵巢癌中表达高于正常卵巢组织,差异无显著性。结论C-kit和PDGFRα与卵巢癌的发生和发展密切相关,应用酪氨酸激酶抑制剂治疗有可能性。
Objective To investigate the expression and significance of tyrosine kinase receptor in ovarian cancer. Methods The expression of C-kit, C-abl and PDGFRα in 20 cases of normal ovarian tissue and 60 cases of ovarian cancer were detected by immunohistochemical SP method. Results The positive rate of at least one tyrosine kinase receptor was 79%. The positive rates of C-kit, C-abl and PDGFRα in ovarian cancer were 58.3%, 70% and 73.3% The positive rate of PDGFRα protein was significantly higher than that of normal ovarian tissue (P <0.01). C-abl expression in ovarian cancer than in normal ovarian tissue, the difference was not significant. Conclusions C-kit and PDGFRα are closely related to the occurrence and development of ovarian cancer. It is possible to treat with tyrosine kinase inhibitors.